603 Page 1 30-Jul-2026 To Company Name/Scheme ACN/ARSN 1. Details of substantial holder (1) Name ACN/ARSN (if applicable) The holder became a substantial holder on 28/07/2026 2. Details of voting power The total number of votes attached to all the voting shares in the company or voting...
Becoming a substantial holder
Filed with ASX ·
6ix hasn’t read this filing yet.
Clarity Pharmaceuticals Ltd. on 6ix
Earlier from Clarity Pharmaceuticals
- Data on SAR-bisPSMA to be presented at EANM
- Clarity receives $9.8 million R&D tax incentive refund
- Clarity signs a Commercial Manufacturing Agreement for Cu-64 SAR-bisPSMA with Nucleus RadioPharma
- Clarity signs a Commercial Manufacturing Agreement
- Co-PSMA data published in the European Urology journal
Later from Clarity Pharmaceuticals
- Quarterly Activities/Appendix 4C Cash Flow Report
- Ceasing to be a substantial holder
- SECuRE update
- Notification regarding unquoted securities - CU6
- Clarity Pharmaceuticals Announces SECuRE Trial Update on 8 GBq 67Cu-SAR-bisPSMA dose level with two additional complete responses
